Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 9:15 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 17,088 matching trials from the live ClinicalTrials.gov search.
Filters: Philadelphia, Pennsylvania Clear all
Completed Not applicable Interventional

Patient Automated Text Hovering for IBD

NCT04388865
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Control, Text-based Clinical Hovering
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Nov 1, 2026, 9:15 AM EST
Completed Phase 3 Interventional Results available

A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A

NCT01731600
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
turoctocog alfa pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
0 Years to 11 Years · Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
24
States / cities
Phoenix, Arizona • Long Beach, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Nov 1, 2026, 9:15 AM EST
Completed Phase 3 Interventional Results available

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

NCT01483144
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Eflornithine, Eflornithine Placebo, Sulindac 150 MG, Sulindac placebo
Drug
Lead sponsor
Cancer Prevention Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
10
States / cities
La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Nov 1, 2026, 9:15 AM EST
Completed Phase 3 Interventional Results available

Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma

NCT00033293
View directory record Official record
Conditions
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
Clinical Observation, Cyclophosphamide, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Prednisone, Therapeutic Immune Globulin
Other · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 8 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2022
U.S. locations
97
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Nov 1, 2026, 9:15 AM EST
Terminated Phase 2 Interventional Results available

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)

NCT04663321
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
MK-1942, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
45
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bellflower, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Nov 1, 2026, 9:15 AM EST
Recruiting Phase 2 Interventional

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

NCT05442216
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Tagraxofusp, Azacitidine, Venetoclax
Drug
Lead sponsor
Joshua Zeidner
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
7
States / cities
Miami, Florida • Orlando, Florida • Buffalo, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Nov 1, 2026, 9:15 AM EST
Completed Phase 3 Interventional Results available

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

NCT05259033
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
IcoSema, Semaglutide 1 mg
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
76
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Nov 1, 2026, 9:15 AM EST
Completed Not applicable Interventional Results available

NuVent™ Revision Study

NCT02284347
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
Electromagnetic Sinus Dilation System (NuVent™)
Device
Lead sponsor
Medtronic Surgical Technologies
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Nov 1, 2026, 9:15 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

NCT03317158
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer
Interventions
Durvalumab (Cohort 1-3), External Beam Radiotherapy (EBRT), Bacillus Calmette-Guérin (BCG), Gemcitabine, Docetaxel, Tremelimumab, Durvalumab (Cohort 4/5), To be determined, Intravesical NAI (Cohorts 6-7), Subcutaneous NAI (Cohort 8)
Drug · Radiation · Biological + 1 more
Lead sponsor
Noah Hahn, M.D.
Other
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
9
States / cities
Phoenix, Arizona • Indianapolis, Indiana • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Nov 1, 2026, 9:15 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Vaginal and Rectal Clostridial Carriage Among Women of Reproductive Age in the United States

NCT01283828
View directory record Official record
Conditions
Clostridium Sordellii, Clostridium Perfringens
Interventions
Not listed
Lead sponsor
Gynuity Health Projects
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
4,977 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
18
States / cities
Montgomery, Alabama • Tucson, Arizona • Boulder, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Nov 1, 2026, 9:15 AM EST
Terminated Phase 1 Interventional Results available

Spironolactone Versus Prednisolone in DMD

NCT03777319
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
Spironolactone, Prednisolone
Drug
Lead sponsor
Kevin Flanigan
Other
Eligibility
4 Years to 7 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Iowa City, Iowa • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Nov 1, 2026, 9:15 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Young Adults' Responses to Anti-smoking Messages

NCT01954407
View directory record Official record
Conditions
Smoking
Interventions
Smoking-Related Messages
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 25 Years
Enrollment
2,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Nov 1, 2026, 9:15 AM EST
Completed Phase 3 Interventional Results available

A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

NCT03525444
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-445/TEZ/IVA, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
53
States / cities
Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 48 more
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Nov 1, 2026, 9:15 AM EST
Active, not recruiting Not applicable Interventional

Clinical Study of the Treovance Stent-Graft for Patients With Abdominal Aortic Aneurysms

NCT02009644
View directory record Official record
Conditions
Abdominal Aortic Aneurysm (AAA)
Interventions
Subjects who receive the Treovance stent-graft
Device
Lead sponsor
Bolton Medical
Industry
Eligibility
18 Years to 85 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Danbury, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Nov 1, 2026, 9:15 AM EST
Completed No phase listed Observational

Predicting the Safety and Effectiveness of Inferior Vena Cava Filters

NCT02381509
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis
Interventions
IVC Filter
Device
Lead sponsor
Carelon Research
Other
Eligibility
18 Years and older
Enrollment
1,428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
53
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Nov 1, 2026, 9:15 AM EST
Completed Not applicable Interventional Results available

Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions

NCT06027593
View directory record Official record
Conditions
Community-acquired Pneumonia, Acute Otitis Media, Pharyngitis
Interventions
Quasi experimental intervention
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
26,139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Nov 1, 2026, 9:15 AM EST
Enrolling by invitation No phase listed Observational

Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Precision Medicine Phase 2 Option 1

NCT04602806
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
5
States / cities
San Francisco, California • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 1, 2026, 9:15 AM EST
Recruiting Phase 2 Interventional

ETHAN - ET for Male BC

NCT05501704
View directory record Official record
Conditions
Male Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Interventions
Tamoxifen, Anastrozole, Degarelix, Abemaciclib
Drug
Lead sponsor
Jose Pablo Leone
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Jacksonville, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Nov 1, 2026, 9:15 AM EST
Completed Early Phase 1 Interventional

Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)

NCT02233504
View directory record Official record
Conditions
High Risk MDS or AML Patients
Interventions
Exjade® (deferasirox, ICL670)
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Nov 1, 2026, 9:15 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Message Testing for CKD

NCT05462158
View directory record Official record
Conditions
Available for Members Text Message, Checked Health Text Message, No Text Message
Interventions
Impact of Nudges on CKD Testing
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
8,637 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Nov 1, 2026, 9:15 AM EST
Active, not recruiting No phase listed Observational

COMPASSION S3 Post-Approval Study

NCT04860765
View directory record Official record
Conditions
Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration, Pulmonary Valve; Obstruction
Interventions
SAPIEN 3 THV
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Nov 1, 2026, 9:15 AM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Feasibility and Validation of an Automated AI-Enabled Deep Ultraviolet (DUV) Cytology Platform for Point-of-Care Oral Cancer Triage

NCT07842211
View directory record Official record
Conditions
Oral Potentially Malignant Lesions, Oral Potentially Malignant Disorders, Oral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity Cancer, Oral Cancer
Interventions
Deep UV-M and AI Cytology Triage
Device
Lead sponsor
Anh Le
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 1, 2026, 9:15 AM EST
Completed Phase 3 Interventional Results available

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

NCT05463744
View directory record Official record
Conditions
Type 1 Diabetes, Diabetes
Interventions
Insulin Efsitora Alfa, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
34
States / cities
Concord, California • Fresno, California • Montclair, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Nov 1, 2026, 9:15 AM EST
Completed Phase 4 Interventional Results available

Promiseb Topical Cream for Cradle Cap

NCT01214434
View directory record Official record
Conditions
Cradle Cap, Infantile Seborrheic Dermatitis
Interventions
Promiseb Topical Cream, Bland emollient
Device · Other
Lead sponsor
Promius Pharma, LLC
Industry
Eligibility
30 Days and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Norwich, Connecticut • Louisville, Kentucky • Newark, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Nov 1, 2026, 9:15 AM EST